#United States #Princeton #Covenant #Hill Research #TriClick

Covenant Continues Investment in Hill Research

Covenant Venture Capital has made a strategic follow-on investment in Hill Research, a key player in the realm of artificial intelligence-driven solutions for clinical trials. This move comes in light of Hill Research's remarkable fourfold revenue growth from 2024 to 2025, underscoring a sustained commitment to fostering innovation at the intersection of AI and life sciences.

The decision to reinvest underscores Covenant's thorough, evidence-based assessment of Hill Research’s performance since its initial investment. The success has not only been reflected in revenue metrics but also in Hill Research's ability to effectively scale its innovative platform, TriClick, which is designed to automate crucial biostatistical and regulatory workflows essential for modern clinical trials.

Hill Research's Growth and Impact

Founded in Princeton, New Jersey, Hill Research has emerged as a leader by offering a solution that significantly enhances the efficiency of the clinical trial process. The company’s platform, TriClick, stands out by streamlining the pipeline from a locked clinical database to FDA submission. It has been reported that TriClick can produce FDA submission-ready outputs up to 300 times faster while also minimizing errors and ensuring traceability of outputs—a critical advantage in the highly regulated environment of clinical research.

According to Hill Research's CEO, Louise Liu, this investment allows the company to further enhance its offerings while upholding the rigorous standards required in the industry. As the demand for more efficient clinical trial processes increases, TriClick is set to play a pivotal role in meeting the needs of pharmaceutical, biotechnology, and clinical research organizations.

As Hill Research anticipates a revenue growth target of 5-7 times by 2026, this latest funding round is aimed at accelerating TriClick’s market adoption, enhancing platform capabilities, and expanding commercial reach. Its current trajectory positions the company for exponential growth, driven by the burgeoning demand for its innovative solutions in biostatistics and regulatory workflows.

The Principled Investment Strategy of Covenant

Covenant’s investment philosophy prioritizes long-term resilience over fleeting market trends. Their focus on structured, disciplined investments resonates deeply within the context of today’s rapidly evolving tech landscape. The commitment to Hill Research is a testament to the company’s consistent execution across various critical areas including product development, customer acquisition, and revenue growth.

René Bastón, a Venture Partner at Covenant, expressed enthusiasm for this partnership, emphasizing the transformative potential of AI in clinical research. He remarked, "Hill Research exemplifies the kind of deep tech innovation we champion. Its AI-driven approach not only speeds up the regulatory process but also minimizes risks for stakeholders in the lifecycle of drug development."

In addition to its financial success, Hill Research has garnered industry recognition, being listed in the 2026 Innovate100. This acknowledgment highlights the pioneering work being done in New Jersey across tech, healthcare, and life sciences. Liu’s recent keynote speech at the 40th AAAI Conference on Artificial Intelligence in Singapore further solidifies Hill Research's reputation in the domain of AI.

Conclusion

Covenant's strategic reinvestment into Hill Research signifies more than just financial backing; it represents a holistic commitment to innovation in clinical trials fueled by advanced AI technologies. As both companies work to push the boundaries of what is possible in clinical research, the future looks promising for the healthcare sector, offering new avenues for faster and more effective treatment solutions to reach the market. With a strong partnership and a shared vision, Covenant and Hill Research are poised to make impactful strides in the landscape of medical research.